Inventiva (NASDAQ:IVA) Stock Price Up 5.7% – Time to Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price was up 5.7% during trading on Wednesday. The stock traded as high as $3.39 and last traded at $3.4450. Approximately 666,986 shares changed hands during trading, a decline of 32% from the average session volume of 977,604 shares. The stock had previously closed at $3.26.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IVA. Cantor Fitzgerald assumed coverage on shares of Inventiva in a report on Friday, July 17th. They set an “overweight” rating for the company. Truist Financial boosted their price target on Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Weiss Ratings lowered Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. Guggenheim increased their price objective on Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $15.86.

Inventiva Price Performance

The company’s 50-day moving average price is $3.94 and its 200 day moving average price is $4.40.

Inventiva (NASDAQ:IVA) last announced its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The firm had revenue of $0.75 million for the quarter. As a group, research analysts predict that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current year.

Institutional Trading of Inventiva

Institutional investors and hedge funds have recently bought and sold shares of the stock. Platt Investment Counsel LLC purchased a new position in shares of Inventiva during the 3rd quarter worth approximately $45,000. Engineers Gate Manager LP raised its position in shares of Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after acquiring an additional 43,280 shares in the last quarter. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Inventiva in the 1st quarter valued at approximately $1,111,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.